#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,1 Gomella LG,2 Sharma P,3 Plimack ER,4 O’Donnell PH,5 Hoffman-Censits J,2 Flaig TW,6 Quinn DI,7 Campogan D,8 Haynes H,8 McCoy C,8 Maher J,8 DeVries T,8 Sheikh N,8 and Lerner SP9 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 NeuACT poster 4541 thumb

1Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA, USA; 3University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Fox Chase Cancer Center, Philadelphia, PA, USA; 5The University of Chicago, Chicago, IL, USA; 6University of Colorado, Denver, CO, USA; 7University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; 8Dendreon Corporation, Seattle, WA, USA; 9Baylor College of Medicine, The Scott Department of Urology, Houston, TX, USA

 

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Winter Meeting / February 25-29 / Scottsdale, AZ
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL